Verdonck L F, Lokhorst H M, Dekker A W, Nieuwenhuis H K, Petersen E J
Department of Haematology, University Hospital Utrecht, The Netherlands.
Lancet. 1996 Mar 23;347(9004):800-1. doi: 10.1016/s0140-6736(96)90871-5.
Allogeneic bone-marrow transplantation (BMT) is associated with the graft-versus-leukaemia effect because of the antileukaemic action of donor lymphocytes. We describe a graft-versus-myeloma effect after BMT in multiple myeloma.
Two patients with recurrent multiple myeloma after allogeneic BMT (T cells partly depleted, 10(5) T cells infused per kg) received leucocyte infusions obtained by leukapheresis from their original marrow donors. The patients were a 48-year-old woman and a 49-year-old man.
Both patients developed graft-versus-host disease and achieved complete remission of myeloma. Chimerism was complete in both patients in that all peripheral blood cells were of donor origin.
We see our results as evidence for a graft-versus-myeloma effect. Using this form of adoptive immunotherapy, we could administer 1000-3000 times more T cells than with the earlier BMT.
由于供体淋巴细胞的抗白血病作用，异基因骨髓移植（BMT）与移植物抗白血病效应相关。我们描述了BMT治疗多发性骨髓瘤后出现的移植物抗骨髓瘤效应。
两名异基因BMT后复发的多发性骨髓瘤患者（T细胞部分清除，每千克输入10⁵个T细胞）接受了通过白细胞单采术从其原骨髓供体获取的白细胞输注。患者分别为一名48岁女性和一名49岁男性。
两名患者均发生了移植物抗宿主病，并实现了骨髓瘤的完全缓解。两名患者的嵌合均完全，即所有外周血细胞均来自供体。
我们将我们的结果视为移植物抗骨髓瘤效应的证据。使用这种过继性免疫疗法形式，我们能够给予比早期BMT多1000 - 3000倍的T细胞。
